STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS) reports a total number of 71,751,201 shares in the capital and 77,686,109 voting rights as of November 30, 2023. For further information, please contact Media Chief of Staff Patricia Sosa Navarro at +33 (0)7 76 77 46 93 or media@cellectis.com, and Investor Relations Chief Business Officer Arthur Stril at +1 (347) 809 5980 or investors@cellectis.com.
Positive
  • None.
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
11/30/202371,751,20177,686,109


For further information on Cellectis, please contact:

Media contact:

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contacts:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment


FAQ

What is the total number of shares in the capital for Cellectis as of November 30, 2023?

Cellectis reports a total number of 71,751,201 shares in the capital.

How many voting rights does Cellectis have as of November 30, 2023?

Cellectis reports a total of 77,686,109 voting rights as of November 30, 2023.

Who can be contacted for media inquiries at Cellectis?

For media inquiries, please contact Patricia Sosa Navarro, Chief of Staff to the CEO, at +33 (0)7 76 77 46 93 or media@cellectis.com.

Who can be contacted for investor relations at Cellectis?

For investor relations, please contact Arthur Stril, Chief Business Officer, at +1 (347) 809 5980 or investors@cellectis.com.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

215.14M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.